Select a Region North America


Rob Arnold

Executive Vice President


Consulting (Strategy Management & Regulatory), HEOR, Managed Markets, Market Access, Market Research, Research & Insights

With over 30 years of consulting and executive leadership throughout Europe, North America, and Asia, Rob Arnold has developed creative solutions to some of the most challenging business situations in Life Sciences.. He’s responsible for innovations and transformations including R&D portfolio management and redirection of some of life science’s largest companies.

Rob speaks at industry forums, business schools and professional associations on strategy in life sciences and has published many professional papers.

He holds an MBA from the Amos Tuck School of Dartmouth College and an MA from Cambridge University.

Articles by Rob Arnold

Reframing the Challenges of Access and ROI

Pharma companies today are being judged not just on their profitability for shareholders, but also on the extent to which their products are accessible to patients. Today’s Environmental, Social and Governance (ESG) investors want to see evidence of corporate responsibility, for which pharmaceuticals’ surrogate measure is access. While companies such as Novo Nordisk and UCB […]

WEBINAR: Sustainability in Pharma: Access and Financial Returns

In addition to the global disruption caused by COVID-19, pharma faces additional pressure to adopt digital technologies, transform long-standing business practices, and accelerate timelines to deliver value for HCPs and patients. Not to mention, the specialty pipeline continues to grow, but therapies for rare diseases are facing significant access challenges. In this webinar, EVERSANA’s Rob […]

How Do You Know Your Portfolio Process Is Adding Value?

In 1998, Rob Arnold, Executive Vice President, teamed with some colleagues to publish an article in the Harvard Business Review that highlighted the practical results obtained by applying modern R&D portfolio thinking to SmithKline Beecham’s late-stage assets. SB publicly claimed that the review process had added $2.6 billion in value to the corporation. That team […]

Interested in scheduling a meeting or speaking event?

Contact Us

  • This field is for validation purposes and should be left unchanged.